The annual incidence of invasive cervical cancer is 6.6/100 000 women in Austria. Within the year 2009, 394 new cases of cervical cancer were diagnosed ([@bib25]). Clinical stage based upon the International Federation of Gynecologists and Obstetricians (FIGO) system reflects the strongest prognostic parameter in patients with cervical cancer ([@bib3]). The FIGO staging system is based upon clinical examination and the system\'s limitations are well appreciated ([@bib13]). A number of other clinico-pathological parameters were shown to have additional prognostic value in predicting patients\' prognosis ([@bib18]). Besides FIGO stage, the most notable prognostic factors are lymph node status and the number of positive lymph nodes, tumour size, parametrial involvement, histologic type, and patients\' age ([@bib9]; [@bib15]; [@bib27]; [@bib22]). The prognostic relevance of other additional parameters such as lymph vascular space invasion (LVSI), histologic grade, and depth of cervical stromal invasion is controversial ([@bib8]; [@bib16]).

Prognostic nomograms have been recently introduced for numerous malignancies, including gynaecologic cancers, to obtain reliable prognostic information tailored to each individual patient ([@bib6]; [@bib1]). Several nomograms were shown to compare favourably to traditional staging systems and their use has been suggested in addition to or even as an alternative to disease stage and other established prognosticators ([@bib14]; [@bib1]). For patients with cervical cancer, a nomogram to predict overall survival (OS) through stages I--IV has not been published so far. The aim of this study was to develop and validate a nomogram for individual prediction of OS in patients diagnosed with invasive cervical cancer.

Patients and Methods
====================

Patients
--------

All consecutive patients diagnosed with cervical cancer at the University Hospitals Vienna and Innsbruck, Austria between 1996 and 2009 were eligible for this study. Clinical data were extracted from the institutions\' prospectively maintained, electronic databases. Institutional review board approval was obtained before the study (IRB approval numbers: 246-2009 (Ethics Committee Medical University of Vienna) and UN4144 (Ethics Committee Medical University of Innsbruck)).

Clinical management
-------------------

Patients were treated and followed according to the international guidelines ([@bib7]; [@bib11]). Briefly, patients diagnosed at stage IA1 disease were treated with conization or simple hysterectomy. If final pathology revealed the presence of LVSI, systematic pelvic and/or paraaortic lymphadenectomy was performed. Patients with stage IA2 were treated either by conization or simple hysterectomy plus systematic pelvic and/or paraaortic lymphadenectomy. Early stage disease FIGO IB1-IIA was managed by radical hysterectomy or trachelectomy plus systematic pelvic and/or paraaortic lymphadenectomy. Patients with positive lymph nodes, parametrial involvement, and positive or close surgical margins were treated with adjuvant, postoperative radiotherapy -- with or without concurrent chemotherapy. Cervical cancer FIGO IIB-IV was treated with primary radio-chemotherapy. In these patients, pelvic and/or paraaortic lymphadenectomy was performed before radio-chemotherapy to allow individualised planning of the radiation field. Extended field radiation was administered to patients with positive lymph nodes in the common iliac region (when paraaortic lymphadenectomy was not performed) or to patients with positive paraaortic lymph nodes ([@bib20]).

Statistical analysis
--------------------

Values are given as mean (standard deviation (s.d.)) when normally distributed or as median (interquartile range (IQR)) at the presence of skewed distribution. *P*-values of \<0.05 were considered statistically significant. We used the statistical software R 2.12.2 for Windows (R Foundation for Statistical Computing, Vienna, Austria).

Overall survival, defined as the time from diagnosis to date of cancer-related death or date of last follow-up for patients who were alive and censored, was defined as the clinical endpoint. Overall survival probabilities were estimated using the Kaplan--Meier method. The following predictors were selected for model development based on previous multivariable analyses ([@bib29]): age (continuous variable), FIGO stage (IV *vs* III *vs* II *vs* IB), the presence of positive lymph nodes (positive *vs* negative), and at the presence of positive lymph nodes lymph node ratio (LNR; continuous variable), parametrial involvement (positive *vs* negative), and tumour size (⩽2 *vs* \>2 cm). Lymph node ratio was defined as the ratio of positive and totally removed lymph nodes, as previously described ([@bib21]). FIGO stages IA were excluded from predictive modelling, as only one event was observed in this group. The model was constructed by estimating a Cox regression model, maximising a likelihood function with a ridge (sum of squared regression coefficients) penalty term to prevent against over-fitting potentially caused by the small number of events in our study (76 events). This type of analysis can deal with data sets in which the number of events per variable is much less than 10, as it prevents overfitting by shrinking the coefficients compared with those by standard Cox regression ([@bib2]). The tuning parameter that controls the amount of shrinkage of regression coefficients by the ridge penalty was optimised by maximising the average of the 10-fold cross-validated partial likelihood over 10 different random partitions of the data into 10-folds ([@bib2]). We decided to include all preselected variables irrespective of significance as nomogram parameters as even non-significant variables must be assumed to have a non-zero effect on survival. Correlation analysis between clinical variables was performed using Spearman and Kendall tau-b rank correlation coefficients. Interactions of any predictors with FIGO stage were evaluated by comparing the cross-validated partial likelihood with and without these interactions. Likewise, we checked for non-linear effects of age or LNR by employing the technique of fractional polynomials and compared the cross-validated partial likelihood with and without nonlinear modelling ([@bib23]). We used the R package glmnet (R Foundation for Statistical Computing) for estimating the model coefficients ([@bib24]).

Model validation
----------------

To determine calibration and discrimination of the model corrected for optimism, we generated 1000 bootstrap samples, which were used as training sets in a bootstrap validation procedure. Specifically, a model was built on each of the 1000 training sets following the same process as described above. The 1000 models were then evaluated on the original data (test set) without modification, estimating 5-year survival probabilities for each patient. For each of the validation models, we constructed a time-dependent receiver operating characteristic (ROC) curve using the survival ROC package of R ([@bib12]). As a measure of discrimination, we computed the median and IQR over the optimism-corrected time-dependent areas under the ROC curves (the c-indices) obtained in each of the models and provide a summary c-index as described previously ([@bib26] and [@bib29]). The calibration of the prediction model was assessed by stratifying the patients, by their risk score, into four quartiles, and evaluating the observed 3- and 5-year survival probability in each quartile by Kaplan--Meier analysis. The mean predicted 3- and 5-year survival probabilities, averaged over the 1000 models, were compared with the averaged observed survival probabilities in calibration plots. If the model is well calibrated, this plot should demonstrate agreement of the predicted and observed survival probabilities.

Results
=======

Patients
--------

A total of 692 consecutive patients with invasive cervical cancer, who were treated at the two institutions between January 1999 and December 2009, were identified. Of these, 528 patients (Department of Gynecology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria, *n*=335 and Innsbruck Medical University, Tirol, Austria, *n*=193) had all nomogram variables available and were included into the analysis. Patients\' characteristics and treatment modalities are shown in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}, respectively.

Survival analyses
-----------------

Median follow-up time was 45.7 months. Patients\' status at last follow-up and recurrence status are shown in [Table 1](#tbl1){ref-type="table"}. Five-year OS rates (standard error) for patients with FIGO stage IA, IB, II, III, and IV were 99.0% (1.0), 88.6% (3.0), 65.8% (5.2), 58.7% (11.0), and 41.5% (14.7), respectively. [Figure 1](#fig1){ref-type="fig"} shows cervical cancer-specific survival with number of patients at risk for cancer-related death for each of the follow-up time points.

Construction and validation of the prediction model
---------------------------------------------------

The FIGO stage, tumour size, age, histologic subtype, LNR, and parametrial involvement were predefined as predictors. The FIGO stage was strongly correlated with tumour size (tau=0.82, *P*\<0.001), parametrial involvement (tau=0.71, *P*\<0.001), LNR (rho=0.42, *P*\<0.001), and age (rho=0.33, *P*\<0.001). Univariate hazard ratios with 95% confidence intervals estimated from univariate Cox regressions are shown in [Table 3](#tbl3){ref-type="table"}. From the multivariable penalised Cox regression model, we computed nomogram points for each predictor by dividing the shrinked coefficients by the largest shrinked coefficient obtained in the analysis (that of LNR), and multiplying by 100 ([Figure 2](#fig2){ref-type="fig"}). Including interactions of FIGO stage with the other predictors did not improve the cross-validated partial likelihood, and neither did the consideration of non-linear effects for LNR or age (data not shown).

The prediction model was internally validated using bootstrap resampling, assessing its optimism-corrected discrimination and calibration. Across the 1000 bootstrap repetitions, the median optimism-corrected summary c-index for predicting survival was 0.723 (25th and 75th percentiles, 0.701 and 0.743, respectively). [Figure 3](#fig3){ref-type="fig"} shows a plot of the time-dependent optimism-corrected c-index, indicating constant and adequate discriminative ability of our prediction model for prediction horizons between 1 and 5 years. The bootstrap-predicted and the actual OS probabilities at 3 and 5 years are shown in the calibration plots ([Figures 4A and B](#fig4){ref-type="fig"}, respectively). The calibration plots describe how far predictions are from actual outcomes and how the prediction model fits the data. The performance of the model appears to be very accurate, within the actual outcomes.

It is important to note that all six covariates must be available to use the nomogram and predict individual patients\' OS. For example, a 45-year-old (7.2 points) with stage IB (0 points), tumour size ⩽2 cm (0 points), squamous cell carcinoma (0 points) with negative lymph nodes (0 points) has a total of 7.2 points, which corresponds to the 3- and 5-year OS probabilities of 95% and 91.8%, respectively. On the other hand, a 45-year-old (7.2 points), with stage IIB (20 points), tumour size ⩽2 cm (0 points), 3 positive out of 15 removed nodes (LNR 0.2 corresponding to 50 points), squamous cell carcinoma (0 points), and parametrial involvement (24 points) has a total of 101.2 points, which corresponds to the 3- and 5-year OS probabilities of 81.1% and 70.5%, respectively.

[Figure 5](#fig5){ref-type="fig"} provides predicted 5-year OS probability sub-grouped by 2009 FIGO stage. We show that, although FIGO stage is an important predictor of 5-year survival probability, the other predictors used in our model add further information useful to discriminate patients with poor or favourable prognosis. Overall, our prediction model combines prognostic factors in a multivariate setting, and thus it is able to discriminate high-, moderate-, and low-risk patients in a detailed way through individualised predictions.

Discussion
==========

Accurate prediction of cancer control after definitive treatment for cervical cancer is important for patient counselling, follow-up, and treatment planning. We constructed a novel nomogram based on a model to predict 3- and 5-year OS for patients with invasive cervical cancer after surgical staging. The nomogram can be used to predict patients\' prognosis individually and more accurate than FIGO stage alone and is based on the following six easily available parameters: FIGO stage, tumour size, histologic type, LNR, age, and parametrial involvement. The model was derived from a European cohort with the entirety of the age spectrum.

FIGO stage is the most important prognostic parameter in patients diagnosed with cervical cancer. Many, but not all, of the known prognostic factors are captured by the FIGO staging system. The FIGO staging system is largely based upon physical examination and a limited number of diagnostic studies ([@bib19]). The limitations of FIGO clinical staging are well appreciated and under-staging occurs ([@bib13]; [@bib22]). Tumour size is an established prognostic parameter that is independent of stage and was originally reflected in FIGO stages IA-IB2. During the 2009 FIGO staging system changes tumour size was added as parameter for stage IIA to distinguish between tumour diameters smaller (IIA1) and larger (IIA2) than 4 cm tumours due to its considerable prognostic value ([@bib9]; [@bib19]). The effect of tumour histology on outcome for women with cervical cancer has been actively debated. Recent studies have shown that adenocarcinomas are more aggressive and are associated with decreased survival for both early and advanced-stage carcinomas ([@bib10]).

Lymph node ratio is a parameter incorporating not only information on the number of positive nodes but also the number of removed nodes. Lymph node ratio is a useful prognostic parameter for patients with cervical cancer and allows stratification of patients into distinctive outcome groups ([@bib21]). It is important to highlight that assigning LNR requires surgical staging with node dissection. The authors are aware that the therapeutic value of pretreatment surgical lymph node staging for patients with advanced stage cervical cancer is still controversial ([@bib4]). At our institution extended-field radiotherapy is recommended when paraaortic nodal disease is proven and we observed excellent pelvic control in these high-risk patients using this concept ([@bib20]). For patients with stage IA1 disease lymph node, dissection was only performed when LVSI was present. As previous studies have shown that the risk for nodal involvement is less than 1% for patients with stage IA1 disease and without LVSI, we assumed negative nodal status and this group of patients was allocated a LNR of 0.0.

Recent studies suggested that younger age is an unfavourable prognostic factor, especially in more advanced stages ([@bib5]). Survival analysis revealed that younger patients showed impaired survival in cohort and therefore age was included into our model. Parametrial involvement significantly influences outcome of patients with cervical cancer but is not reflected in FIGO stages III-IV ([@bib27]). In the Gynecologic Oncology Group (GOG), 49 study patients with apparent stage I disease with and without parametrial involvement were shown to have 70% and 85% 3-years disease-free intervals, respectively ([@bib9]). Patients found to have parametrial involvement will usually receive primary or adjuvant radiation therapy after surgery ([@bib7]).

A nomogram is a graphic prediction tool that incorporates clinical risk factors already included in established staging systems, as well as other additional, clinical, and pathologic factors known to have an impact on outcome. A distinct advantage of a nomogram is that all the critical variables that determine outcome can be graphically displayed ([@bib14]). Prognostic nomograms attempt to combine important clinical factors to quantify the risk as precisely as possible to accurately predict clinical outcome. Clinical nomograms have been developed as predictive tools for outcomes in gynaecologic malignancies such as endometrial and ovarian cancer ([@bib6]; [@bib1]). For the estimation of outcome of patients with cervical cancer, few nomograms have been published so far ([@bib17]; [@bib28]). This nomogram is the first to predict OS through stages I--IV that was constructed based on data of a mainly Caucasian patient cohort.

Despite having achieved prognostic accuracy, our study is not devoid of limitations. The multi-institutional nature of our data set may be interpreted as a limitation, given that it groups the contribution of multiple surgeons and pathologists and relies on different surgical approaches, in addition to other differences that might distinguish the two contributing centres. However, this limitation could also be seen as strength, as it makes our conclusions more general and increases the available sample size, which is important given the low event rate. Despite combining data from two institutions, we observed a limited number of events (i.e., cancer-related deaths). To take this into account, the model coefficients were computed using the recently developed 'ridge\' method. This approach was originally designed to deal with situations where the number of predictors exceeds the number of events by large ('*P*\>\>*n*\') such as in genomic applications, and was recently found to be superior to other methods also for prediction in 'classical\' ('*P*\<*n*\') settings, where less than 10 events per variable are available ([@bib2]). In ridge regression, the amount of penalisation is driven by predictive performance in cross-validation (cross-validated partial likelihood). This 'automatism\' guards against over-fitting a model. However, shortage of data, caused by too many variables compared with the number of events, may lead to higher penalisation, and reduce ability of a model to predict the outcome in the extremes. Therefore, we created calibration plots based on internal cross-validation by bootstrap resampling, which showed an almost perfect agreement of observed and predicted event rates. Nevertheless, external validity of our model is a crucial prerequisite to clinical applicability, and can only be assessed by confirming results in a reasonably large independent validation cohort with an adequate follow-up period. Another potential limitation of our model as typical for nomograms is that construction is based on retrospective data. Therefore, our study might be limited by biases such as lack of random assignment, patient selection, and incomplete data acquisition. Nomogram variables were missing in a significant number (*n*=164) of patients of our cohort. Mostly information on parametrial involvement and exact tumour size was incompletely documented in the cases that were excluded from analysis, especially in patients with advanced stage cervical cancer.

In summary, we present the first model to predict 3- and 5-year survival for patients with cervical cancer after surgical staging that is applicable through stages I--IV. The model was developed in a relatively large European, mainly Caucasian, cohort and can be applied for prediction by means of the presented nomogram or, more conveniently, by an online prediction tool (available at <http://www.ccc.ac.at/gcu>).
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![Time-dependent discrimination curves. Optimism-corrected area under the ROC (AUROC): median over 1000 bootstrap replicates shown as solid line, dashed lines denote 25th and 75th percentiles.](bjc2012340f3){#fig3}

![Cervical cancer OS nomogram calibration plots: (**A**) 3-year and (**B**) 5-year nomogram calibration curve. Nomogram-predicted OS rates are plotted on the *x*-axis, actual OS are plotted on the *y*-axis. The dashed line represents the ideal fit where the nomogram-predicted probability matches the observed probability from Kaplan--Meier estimates.](bjc2012340f4){#fig4}
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###### Patients\' characteristics

  **Parameter**                                   ***N*** **(%) or mean (s.d.)**
  ---------------------------------------------- --------------------------------
  Total number of patients enroled                             528
  Age at first diagnosis (years)                           47.9 (13.5)
                                                                 
  *FIGO stage*                                   
   FIGO IA1                                                111 (21.0%)
   FIGO IA2                                                 11 (2.1%)
   FIGO IB1                                                169 (32.0%)
   FIGO IB2                                                 44 (8.3%)
   FIGO IIA                                                 24 (4.5%)
   FIGO IIB                                                118 (22.3%)
   FIGO IIIA                                                 3 (0.6%)
   FIGO IIIB                                                34 (6.4%)
   FIGO IVA                                                  7 (1.3%)
   FIGO IVB                                                  7 (1.3%)
                                                                 
  *Tumour size*                                  
   \<2cm                                                   215 (40.7%)
   ⩾2 cm                                                   313 (59.3%)
                                                                 
  *Histologic subtype*                           
   Squamous cell carcinoma                                 421 (79.7%)
   Adenocarcinoma                                           86 (16.3%)
   Others                                                   21 (4.0%)
                                                                 
  *Lymph node status*                            
   Negative                                                389 (73.7%)
   Positive                                                139 (26.3%)
   Lymph node ratio[a](#t1-fn2){ref-type="fn"}             0.058 (0.16)
                                                                 
  *Parametrial involvement*                      
   No                                                      358 (67.8%)
   Yes                                                     170 (32.2%)
                                                                 
  *Recurrence status*                            
   No. of patients with recurrent disease                  110 (20.8%)
                                                                 
  *Status at last observation*                   
   Alive or non-cancer related death                       451 (85.4%)
   Cancer-related death                                     77 (14.6%)

Abbreviations: FIGO=International Federation of Gynecologists and Obstetricians; s.d.=standard deviation.

Lymph node ratio is defined as ratio of positive and totally removed lymph nodes.

###### Treatment of 528 patients diagnosed with invasive cervical cancer

  **Treatment**                            ***N*** **(%)**
  ---------------------------------------- -----------------
  *Surgery*                                
   Conization                              72 (13.6%)
   Simple hysterectomy                     39 (7.4%)
   Radical hysterectomy or trachelectomy   217 (41.1%)
   Pelvic exenteration                     2 (0.4%)
   Pelvic lymphadenectomy                  377 (71.4%)
   Paraaortic lymphadenectomy              130 (24.6%)
                                            
  *Radiotherapy*                           
   No                                      286 (54.2%)
   Yes                                     242 (45.8%)
                                            
  *Chemotherapy*                           
   No                                      353 (76.9%)
   Yes                                     175 (33.1%)

###### Univariate hazard ratios for overall survival for predictors that were used in the nomogram

  **Variable**                     **Univariate hazard ratio (95% confidence interval)**
  -------------------------------- -------------------------------------------------------
  Age (continuous, per decade)     1.14 (0.97, 1.35)
                                    
  *FIGO stage*                      
   FIGO IA                         1 (ref.)
   FIGO IB                         12.1 (1.6, 90.1)
   FIGO II                         36.3 (5.0, 264.9)
   FIGO III                        67.6 (8.8, 518.5)
   FIGO IV                         111.1 (13.6, 903.8)
                                    
  *Tumour size*                     
   \<2 cm                          1 (ref.)
   2--4 cm                         6.7 (3.0, 14.7)
   \>4 cm                          8.2 (3.8, 17.5)
                                    
  *Histologic subtype*              
   Squamous cell carcinoma         1 (ref.)
   Adenocarcinoma                  1.5 (0.89, 2.6)
   Other histologies               1.8 (0.7, 5.1)
                                    
  *Lymph node status*               
   Negative lymph nodes            1 (ref.)
   Any positive lymph nodes        4.8 (3.1, 7.7)
                                    
  *If any positive lymph nodes:*    
   Lymph node ratio (continuous)   3.4 (1.3, 9.0)
                                    
  *Parametrial involvement*         
   No                              1 (ref.)
   Yes                             4.7 (2.9, 7.5)

Abbreviation: FIGO=International Federation of Gynecologists and Obstetricians.
